 KING OF PRUSSIA, Pa., May 16, 2021 PRNewswire -- Global biotherapeutics leader CSL Behring today announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that included more than 82,000 high-risk patients with recent acute coronary syndrome ACS. 